Renovaro Biosciences (RENB) Announces $15M in Equity Committed

Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announces that it has $15 million in additional equity committed at a price per share of $1.00 and one privately placed cash warrant exercisable at $1.50 with a one year term.

David Weinstein, Chief Executive Officer of Renovaro, commented, “We believe this new capital now enables the company to accelerate our focus on revolutionizing healthcare by combining advanced diagnostic and personalized immunotherapy for early diagnosis, better-targeted treatments, and drug discovery.”

You May Also Be Interested In

• FIS launches embedded banking platform for U.S. banks
• CPKC sets August grain transport record to open new crop year
• Tyson Foods updates guidance